Myelin alters the inflammatory phenotype of macrophages by activating PPARs

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Bogie, Jeroen FJ ^a   Jorissen, Winde ^a   Mailleux, Jo ^a   Nijland, Philip G ^b   Zelcer, Noam ^c   Vanmierlo, Tim ^a   Van Horssen, Jack ^b   Stinissen, Piet ^a   Hellings, Niels ^a   Hendriks, Jerome JA ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Macrophages; Multiple sclerosis; Myelin; Neuroinflammation; Phosphatidylserine; PPAR

Indexed keywords

EID: 85005822614     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-43     Document Type: Article

References (65)

1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L: Axonal transection in the lesions of multiple sclerosis. N Engl JMed 1998, 338: 278-285. 10.1056/NEJM199801293380502
2. Barnett MH, Henderson AP, Prineas JW: The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler 2006, 12: 121-132. 10.1191/135248506ms1304rr
3. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD: Macrophages and neurodegeneration. Brain Res Brain Res Rev 2005, 48: 185-195. 10.1016/j.brainresrev.2004.12.008
4. Miller E, Mrowicka M, Zolynski K, Kedziora J: [Oxidative stress in multiple sclerosis]. PolMerkur Lekarski 2009, 27: 499-502.
5. Sun X, Wang X, Chen T, Li T, Cao K, Lu A, Chen Y, Sun D, Luo J, Fan J, et al.: Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-dependent inflammatory response in murine system. PLoS One 2010, 5: e9380. 10.1371/journal.pone.0009380
6. van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Dopp EA, Dijkstra CD: Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J Neuroimmunol 1996, 70: 145-152. 10.1016/S0165-5728(96)00110-5
7. Williams K, Ulvestad E, Waage A, Antel JP, McLaurin J: Activation of adult human derived microglia by myelin phagocytosis in vitro. J Neurosci Res 1994, 38: 433-443. 10.1002/jnr.490380409
8. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. NatRevImmunol 2005, 5: 953-964.
9. Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci 2008, 13: 453-461. 10.2741/2692
10. Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat RevImmunol 2008, 8: 958-969.
11. Mosley K, Cuzner ML: Receptor-mediated phagocytosis of myelin by macrophages and microglia: effect of opsonization and receptor blocking agents. Neurochem Res 1996, 21: 481-487. 10.1007/BF02527713
12. Bogie JF, Stinissen P, Hellings N, Hendriks JJ: Myelin-phagocytosing macrophages modulate autoreactive T cell proliferation. J Neuroinflammation 2011, 8: 85. 10.1186/1742-2094-8-85
13. Bogie JF, Timmermans S, Huynh-Thu VA, Irrthum A, Smeets HJ, Gustafsson JA, Steffensen KR, Mulder M, Stinissen P, Hellings N, Hendriks JJ: Myelin-derived lipids modulate macrophage activity by liver x receptor activation. PLoS One 2012, 7: e44998. 10.1371/journal.pone.0044998
14. Boven LA, van Meurs M, van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, Aerts JM, Amor S, Nieuwenhuis EE, Laman JD: Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 2006, 129: 517-526.
15. Liu Y, Hao W, Letiembre M, Walter S, Kulanga M, Neumann H, Fassbender K: Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 2006, 26: 12904-12913. 10.1523/JNEUROSCI.2531-06.2006
16. van Rossum D, Hilbert S, Strassenburg S, Hanisch UK, Bruck W: Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype. Glia 2008, 56: 271-283. 10.1002/glia.20611
17. Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, Amor S, Teunissen CE, van Horssen J, Dijkstra CD: Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 2013, 10: 35. 10.1186/1742-2094-10-35
18. Blewett MM: Lipid autoreactivity in multiple sclerosis. Med Hypotheses 2010, 74: 433-442. 10.1016/j.mehy.2009.10.003
19. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM: A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000, 405: 85-90. 10.1038/35011084
20. Zwaal RF, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89: 1121-1132.
21. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101: 890-898. 10.1172/JCI1112
22. Hoffmann PR, Kench JA, Vondracek A, Kruk E, Daleke DL, Jordan M, Marrack P, Henson PM, Fadok VA: Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol 2005, 174: 1393-1404.
23. Huynh ML, Fadok VA, Henson PM: Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002, 109: 41-50.
24. De Simone R, Ajmone-Cat MA, Tirassa P, Minghetti L: Apoptotic PC12 cells exposing phosphatidylserine promote the production of anti-inflammatory and neuroprotective molecules by microglial cells. J Neuropathol Exp Neurol 2003, 62: 208-216.
25. Mukundan L, Odegaard JI, Morel CR, Heredia JE, Mwangi JW, Ricardo-Gonzalez RR, Goh YP, Eagle AR, Dunn SE, Awakuni JU, et al.: PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med 2009, 15: 1266-1272. 10.1038/nm.2048
26. Coll T, Barroso E, Alvarez-Guardia D, Serrano L, Salvado L, Merlos M, Palomer X, Vazquez-Carrera M: The role of peroxisome proliferator-activated receptor beta/delta on the inflammatory basis of metabolic disease. PPAR Res 2010., 2010: ID 368467
27. Degenhardt T, Saramaki A, Malinen M, Rieck M, Vaisanen S, Huotari A, Herzig KH, Muller R, Carlberg C: Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta. J Mol Biol 2007, 372: 341-355. 10.1016/j.jmb.2007.06.091
28. Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, Chang S, Lau P, Fowler AJ, Chuang G, Moser AH, et al.: Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 2004, 122: 971-983. 10.1111/j.0022-202X.2004.22412.x
29. Aramaki Y, Nitta F, Matsuno R, Morimura Y, Tsuchiya S: Inhibitory effects of negatively charged liposomes on nitric oxide production from macrophages stimulated by LPS. Biochem Biophys Res Commun 1996, 220: 1-6. 10.1006/bbrc.1996.0346
30. De SR, Ajmone-Cat MA, Nicolini A, Minghetti L: Expression of phosphatidylserine receptor and down-regulation of pro-inflammatory molecule production by its natural ligand in rat microglial cultures. J Neuropathol Exp Neurol 2002, 61: 237-244.
31. Harel-Adar T, Ben Mordechai T, Amsalem Y, Feinberg MS, Leor J, Cohen S: Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci USA 2011, 108: 1827-1832. 10.1073/pnas.1015623108
32. Hoffmann PR, DeCathelineau AM, Ogden CA, Leverrier Y, Bratton DL, Daleke DL, Ridley AJ, Fadok VA, Henson PM: Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J Cell Biol 2001, 155: 649-659. 10.1083/jcb.200108080
33. Ma HM, Wu Z, Nakanishi H: Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages. Lab Invest 2011, 91: 921-931. 10.1038/labinvest.2011.54
34. Otsuka M, Tsuchiya S, Aramaki Y: Involvement of ERK, a MAP kinase, in the production of TGF-beta by macrophages treated with liposomes composed of phosphatidylserine. Biochem Biophys Res Commun 2004, 324: 1400-1405. 10.1016/j.bbrc.2004.09.198
35. Zhang J, Fujii S, Wu Z, Hashioka S, Tanaka Y, Shiratsuchi A, Nakanishi Y, Nakanishi H: Involvement of COX-1 and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced prostaglandin E2 production by microglia. J Neuroimmunol 2006, 172: 112-120. 10.1016/j.jneuroim.2005.11.008
36. Hong C, Tontonoz P: Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008, 18: 461-467. 10.1016/j.gde.2008.07.016
37. Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 2004, 10: 355-361. 10.1038/nm1025
38. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B, Lee CH: Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 2008, 7: 485-495. 10.1016/j.cmet.2008.04.002
39. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW, Chawla A: Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 2008, 7: 496-507. 10.1016/j.cmet.2008.04.003
40. Ramos GC, Fernandes D, Charao CT, Souza DG, Teixeira MM, Assreuy J: Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator-activated receptors (PPARs) in vivo. Br J Pharmacol 2007, 151: 844-850. 10.1038/sj.bjp.0707302
41. Ho PP, Kanter JL, Johnson AM, Srinagesh HK, Chang EJ, Purdy TM, van Haren K, Wikoff WR, Kind T, Khademi M, et al.: Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci Transl Med 2012, 4: 137-173.
42. Monastra G, Cross AH, Bruni A, Raine CS: Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination. Neurology 1993, 43: 153-163. 10.1212/WNL.43.1_Part_1.153
43. Kleinclauss F, Perruche S, Masson E, de Carvalho BM, Biichle S, Remy-Martin JP, Ferrand C, Martin M, Bittard H, Chalopin JM, et al.: Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ 2006, 13: 41-52. 10.1038/sj.cdd.4401699
44. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, et al.: Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004, 64: 5839-5849. 10.1158/0008-5472.CAN-04-0465
45. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC: L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003, 171: 1232-1239.
46. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, et al.: PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007, 6: 137-143. 10.1016/j.cmet.2007.06.010
47. Lovren F, Pan Y, Quan A, Szmitko PE, Singh KK, Shukla PC, Gupta M, Chan L, Al-Omran M, Teoh H, Verma S: Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 2010, 299: H656-663. 10.1152/ajpheart.00115.2010
48. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A: Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447: 1116-1120. 10.1038/nature05894
49. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, Drew PD, Racke MK: Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168: 2508-2515.
50. Polak PE, Kalinin S, Dello Russo C, Gavrilyuk V, Sharp A, Peters JM, Richardson J, Willson TM, Weinberg G, Feinstein DL: Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 168: 65-75. 10.1016/j.jneuroim.2005.07.006
51. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT: Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002, 51: 694-702. 10.1002/ana.10206
52. Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben LH, Drew PD, Stuve O, Lovett-Racke AE, Racke MK: Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-(alpha) agonists in autoimmune disease. J Immunol 2009, 182: 4479-4487. 10.4049/jimmunol.0713927
53. Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ: Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 2010, 130: 572-588. 10.1111/j.1365-2567.2010.03261.x
54. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK: Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004, 172: 5790-5798.
55. Natarajan C, Bright JJ: Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002, 3: 59-70. 10.1038/sj.gene.6363832
56. Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, Tashiro K, Onoe K: Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol 2001, 116: 40-48. 10.1016/S0165-5728(01)00285-5
57. Grand Pre T, Nakamura F, Vartanian T, Strittmatter SM: Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000, 403: 439-444. 10.1038/35000226
58. Kotter MR, Li WW, Zhao C, Franklin RJ: Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 2006, 26: 328-332. 10.1523/JNEUROSCI.2615-05.2006
59. Kotter MR, Zhao C, van Rooijen N, Franklin RJ: Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005, 18: 166-175. 10.1016/j.nbd.2004.09.019
60. Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, He Z: Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002, 417: 941-944. 10.1038/nature00867
61. Norton WT, Poduslo SE: Myelination in rat brain: changes in myelin composition during brain maturation. J Neurochem 1973, 21: 759-773. 10.1111/j.1471-4159.1973.tb07520.x
62. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G, Probert L: Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998, 153: 801-813. 10.1016/S0002-9440(10)65622-2
63. Nelissen K, Smeets K, Mulder M, Hendriks JJ, Ameloot M: Selection of reference genes for gene expression studies in rat oligodendrocytes using quantitative real time PCR. J Neurosci Methods 2010, 187: 78-83. 10.1016/j.jneumeth.2009.12.018
64. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3: 1-11.
65. Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T, Castro A: Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci USA 2010, 107: 12564-12569. 10.1073/pnas.0914191107